• Article highlight
  • Article tables
  • Article images

Article History

Received : 27-07-2020

Accepted : 13-08-2020



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 605

PDF Downloaded: 507


Get Permission Sundararaju, Poovathai, and Batcha: Comparison of adjuvant effects of intrathecal magnesium sulfate and dexmedetomidine with hyperbaric bupivacaine


Introduction

Infraumblical surgeries are commonly done under central neuraxial blockade. Spinal anaesthesia is preferred for its rapid onset, higher block, fewer failure rates, and cost -efficiency. However, the role of spinal anaesthesia is restricted in prolonged procedures, for its shorter duration of action and less postoperative analgesia when only local anaesthetics are used. This is overcome by adding adjuvants to local anaesthetics. Hence,various adjuvants like opioids, magnesium sulphate, clonidine, and dexmedetomidine were studied to prolong spinal anaesthesia.1, 2, 3, 4 Each adjuvant has its limitations and requires strict observation for any adverse effects. Best modality would be to deliver better analgesia with lesser opioid use and augment patient satisfaction and early rehabilitation.

Dexmedetomidine is an α2-adrenergic receptor agonist, with a relatively higher selective ratio of α2 to α1 receptor (1620:1 as compared to 220:1 for clonidine).5 Intrathecal α2 agonists exerts its antinociceptive effects on somatic and visceral pain.6 It has been the focus of interest in anaesthetic procedures, as it produces dose-dependent analgesia,sedation(involving spinal and supraspinal sites) without respiratory depression, secondary to activation of central α2-adrenoceptors in the locus coeruleus.7 Based on earlier studies, it is clear that 5 µg dexmedetomidine when added to hyperbaric bupivacaine would provide better postoperative analgesia, at the same time with minimal side effects.8, 9, 10 In the present study, the appropriate dosage of intrathecal dexmedetomidine with no neurotoxic effects was administered to study participants.11, 12

Magnesium sulfate prevents the development of central sensitization of pain by antagonistic action on spinal cord N-methyl-D-aspartate receptors. The calcium channel blocking property of magnesium sulfate also contributes to its antinociceptive effect.13 Intrathecal magnesium sulfate improved postoperative analgesia in orthopaedic cases.14, 15 Magnesium sulphate plus 25 μg fentanyl added to 10 mg bupivacaine enhanced spinal anaesthesia duration in lower extremity surgery.16 Similarly, a study done by Khezri et al, shows optimal dosage of spinal magnesium sulfate to prolong the intrathecal opioid analgesia duration without additional side effects.17

In our study, we have compared the adjuvant effects of intrathecal magnesium sulphate and intrathecal dexmedetomidine added to hyperbaric bupivacaine, on block characteristics.

Materials and Methods

The prospective, randomized, double-blind, placebo-controlled study was conducted in the Annapoorna Medical College and hospital between June 2019 to December 2019. 90 patients planned for elective surgeries involving infraumbilical regions by spinal anaesthesia were involved in our study. Patients aged 18-50 years of both gender with American society of Anaesthesiologist physical status(ASA)PS I and II were included for our study. Exclusion criterion was contraindications for spinal anaesthesia, patients taking antihypertensives and antidepressant medications, dysrhythmias, and pregnant patients.

Institutional ethical committee approval obtained. Consent (written informed) of all the participants was obtained. Patients were allocated into three groups randomly (Group B, D, and M). Patients in 3 groups received drugs as follows. Group B- 15 mg hyperbaric bupivacaine +0.5 ml normal saline. Group D-15 mg hyperbaric bupivacaine +5 μg dexmedetomidine in 0.5 ml normal saline. Group M-15 mg hyperbaric bupivacaine +50 mg magnesium sulphate in 0.5 ml normal saline. All patients were given anxiolytic tablet alprazolam 0.5 mg, the night before surgery.

In the operation room, electrocardiogram (ECG), pulse oximeter(Spo2),and non-invasive blood pressure monitor were connected to patients and baseline values noted. Intravenous (IV) cannula was secured and preloading with ringer lactate 10 ml/kg was done. The study drug loaded in a 5 ml syringe was given in a coded form to the anaesthesiologist giving anaesthesia who was blinded to the drug given to him/her. Under strict asepsis, a lumbar puncturewas done at L2-3 or L3-4 interspace using a 26-gauge Quincke spinal needle with patients in sitting position. Immediately after injecting the study drug, patients were placed supine. Oxygen 2 L/min given through face mask if saturation falls below 90%.

Hypotension, defined as >30% fall in systolic blood pressure from baseline value or mean arterial blood pressure <60 mmHg was treated with i.v. fluids, inj.ephedrine 6 mg i.v based on response. Bradycardia, if heart rate < 50 beats per min patient was awakened and when heart rate does not increase, was treated with Inj.Atropine 0.3-0.6 mg i.v. Other adverse effects such as nausea, vomiting, shivering, respiratory depression, sedation, and pruritus were noted.

Intraoperative data were noted by the anaesthesiologist. The sensory level was assessed by the absence of pinprick sensation, using a 25-gauge blunt needle every 2 minutes till it reaches the highest dermatomal level. Surgery was started after the accomplishment of the loss of pinprick sensation at the T8 level. Time to two dermatomes sensory regression was noted. Time taken to return of pinprick sensation at S1 dermatome was taken as duration of sensory blockade.

The motor block level was examined by Modified Bromage score.18 (the duration to reach Bromage score 3 was considered as motor block onset time) Motor block onset was when Bromage 3 score attained. Time to achieve full regression of motor block which corresponds to the score of Bromage 0 was taken as duration of motor block. The time of spinal injection was taken as time zero and all durations were assessed.

The pain was assessed using the visual analogue scale (VAS). 19 Time when the first request for rescue analgesics made or VAS Score > 4 was noted as period of effective analgesia. Rescue analgesia was an intravascular infusion of paracetamol 1gm and repeated 8th hourly.

The data recorded were collected and tabulated. Analysis of data was done using Statistical Package for Social Sciences (SPSS Inc. Chicago, IL, USA) Windows-based version 16.0. Fisher’s ‎exact ‎test or chi-square test was used to study nominal categorical data between groups. Data were tabulated as either means and standard deviations. The comparisons of continuous variables which were normally distributed amongst the groups was done by one-way analysis of variance (ANOVA) and, if relevant, the Bonferroni test was used for post hoc analysis. p< 0.05 values were considered statistically significant.

Results

A total of 30 participants in each group were included in the study. Group B received bupivacaine alone, Group D bupivacaine with dexmedetomidine and Group M bupivacaine with magnesium sulfate.

The demographic profile (Table 1) was compared among the three study Groups. The gender distribution ASA distribution of study participants was depicted in Figure 1 and Figure 2 respectively. The mean sensory onset time (min) was achieved earlier in Group D (2.63 ± 0.66) and delayed in Group M (6.35 ± 0.87) when compared to Group B (2.93 ± 0.785) (Table 2). When compared to Group B (11.23 ± 1.331), maximum sensory block (min) was attained faster in Group D (9.27 ± 1.172) and delayed in Group M (12.40 ± 1.32) (Table 2). Time to 2 segment regression (min) was prolonged in Group D (152.03 ± 10.307) when compared to Group B (71.70 ± 9.520) and Group M (90.43 ± 7.060) (Table 2). There was a significant delay in time for rescue analgesia (min) in Group D (363.00 ± 22.537) and Group M (261.25 ± 21.75). When compared to Group B (6.60 ± 1.163), the motor onset time in (min) was early in the Group D (5.33 ± 0.711) and delayed in the Group M (7.45 ± 1.35). Motor duration (min) was less in Group M (165 ± 31.55) and prolonged in Group D (423.00 ± 12.360) and when compared to Group B(219.23 ± 14.875) (Table 2). There was no significant change in heart rate and mean arterial pressure in all the three study groups. (Figure 3 and Figure 4).

Table 1

Demographic profile of the study participants

Parameters

Group B

Group D

Group M

p value

Age in years

40.16 ± 10.12

41.85 ± 9.85

42.56 ± 7.5

0.5876

Height in cms

161.70 ± 8.38

165.23 ± 7.32

163.73 ± 9.32

0.1625

Weight in kgs

60.33 ± 7.21

64.32 ± 8.56

63.54 ± 7.64

0.0960

Figure 1

Gender wise distribution of study participants

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/8930c2f5-da12-458c-9666-e1be8794b40c/image/3df04b24-5660-432a-a5ac-8d57eb2c839c-uimage.png

Figure 2

ASA grade distribution of study participants

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/8930c2f5-da12-458c-9666-e1be8794b40c/image/a5a9501d-fed7-4240-b55e-dec72a301cc3-uimage.png

Table 2

Characteristics of spinal anaesthesia in study participants

Parameters

Group B (mean ± SD)

Group D(mean ± SD)

Group M (mean ± SD)

F value

p value

Sensory onset time (min)

2.93 ± 0.785

2.63 ± 0.66

6.35 ± 0.87

638.892

0.000*

Time to maximum sensory block (min)

11.23 ± 1.331

9.27 ± 1.172

12.40 ± 1.32

138.174

0.000*

Time to 2 segment regression (min)

71.70 ± 9.520

152.03 ± 10.307

90.43 ± 7.060

1933.144

0.000*

Time for rescue analgesia (min)

230.83 ± 13.332

363.00 ± 22.537

261.25 ± 21.75

679.176

0.000*

Motor onset time (min)

6.60 ± 1.163

5.33 ± 0.711

7.45 ± 1.35

83.503

0.000*

Motor duration (min)

219.23 ± 14.875

423.00 ± 12.360

165 ± 31.55

3648.37

0.000*

Figure 3

MAP Changes during the study in three Groups

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/8930c2f5-da12-458c-9666-e1be8794b40c/image/0671bf67-fb2a-4b37-8b25-99ec119b0d2c-uimage.png

Figure 4

Pulse rate changes during the study in three Groups

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/8930c2f5-da12-458c-9666-e1be8794b40c/image/d6aaa289-44fb-47f2-a939-dec006f1e7e3-uimage.png

Figure 5

Number of cases with symptoms in different Groups

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/8930c2f5-da12-458c-9666-e1be8794b40c/image/f5e71d65-f79f-43c4-a580-dad620f00609-uimage.png

Discussion

The effects of spinal bupivacaine, when supplemented with intrathecal dexmedetomidine, revealed the shorter onset time for both sensory and motor block. Also, the period of sensory and motor blocking effects of spinal bupivacaine was prolonged when supplemented with intrathecal dexmedetomidine. Our study concurs with Kaya et al.20 and Kanazi et al.,2 where there is prolonged bupivacaine spinal anesthesia when dexmedetomidine was used as an adjuvant.20 Moreover, Al-Mustafa et al. 200921 showed that prolonged duration of motor block was attributed to the appropriate dosage and volume of intrathecal dexmedetomidine. Furthermore, a study done in animals showed significant analgesic effect and increased duration of the sensory and motor block when intrathecal dexmedetomidine was given along with bupivacaine.22 The sensory block prolongation by intrathecal dexmedetomidine was by depressing the C-fibre transmitter release and also by postsynaptic dorsal horn neurons hyperpolarization.23 Intrathecal dexmedetomidine prolong motor block by binding to α2 adrenoreceptors of motor neurons located in the spinal cord dorsal horn.24 Although there was no significant bradycardia and hypotension intraoperatively, postoperative hypotension and bradycardia were obvious in participants receiving intrathecal dexmedetomidine with bupivacaine (Figure 5). Compared with the use of bupivacaine for spinal anaesthesia for lower segment caesarean section, adding intrathecal dexmedetomidine during spinal anaesthesia can significantly shorten the onset time and decrease the rate of shivering during anesthesia.25

The sensory and motor blockade onset time was delayed in Group M compared to other two groups as depicted in Table 2. The sensory block duration was prolonged, whereas motor block duration was less when compared to Group B. Our study is supported by Zhong et al., who showed intravenous magnesium sulfate can accelerate the sensory block onset and lenghthen the sensory block and spinal anesthesia duration.26 Banihashem et al., reported that the intrathecal magnesium sulfate delayed the onset of sensory blockade which was not advisable for cesarean section.27 Ozalevli M et al. observed in lower extremity surgery patients, that there was a significant delay in the onset of motor and sensory blockade but prolonged the period of anaesthesia without additional side-effects when intrathecal magnesium sulfate was added to bupivacaine and fentanyl spinal anaesthesia.15 Compared to three Groups, in Group M, shivering, hypotension, and bradycardia were less marked (Figure 5). These findings are supported by Omar et al.28 and He L at al,29 who showed magnesium sulfate causes peripheral vasodilation which improves the cutaneous circulation thereby decreasing the incidence of shivering. In a randomized control trial, reported by Morrison AP, et al., it was found that the incidence of hypotension and pruritus was similar in Group which bupivacaine alone and Group which received both bupivacaine plus magnesium sulfate. This is contrary to what is reported in this study.30 The slow rate of injection would induce lower incidence of hypotension and thus better hemodynamic stability induced by spinal Bupivacaine for Caesarean section.31

In our study, both Group D and Group M have produced remarkable intraoperative analgesia with stable hemodynamics. The hemodynamic stability that was observed in this study is attributed mainly to good preloading. Furthermore, the associated sympathetic block is usually near-maximal with the doses used for spinal anaesthesia. Moreover, the time required for the first dose of rescue analgesic was more for Group D when compared to Group M. The duration of two-segment sensory block regression was remarkably slower in Group D when compared to Group M and Group B. However, different doses of the local anaesthetic with the same adjuvants were not considered in the study and the same can be done in the future studies.

Conclusion

Thus our study proved the superiority of bupivacaine and dexmetidomidine combination over bupivacaine alone for the surgeries which require prompt onset and longer duration of analgesia. However, bupivacaine with magnesium sulfate can be preferred over bupivacaine alone for short surgical procedures that permit sensory blockade onset delay.

Source of Funding

None.

Conflict of interest

None.

Acknowledgment

Sincerely acknowledge the faculty and staff of our Hospital for the support.

References

1 

N Elia X Culebras C Mazza E Schiffer M R Tramèr Clonidine as an adjuvant to intrathecal local anesthetics for surgery: Systematic review of randomized trialsReg Anesth Pain Med20083315967

2 

GE Kanazi MT Aouad SI Jabbour-Khoury MD Al Jazzar MM Alameddine R Al-Yaman Effect of low-dose dexmedetomidine or clonidine on the characteristics of bupivacaine spinal blockActa Anaesthesiol Scand2006502222710.1111/j.1399-6576.2006.00919.x

3 

M Boussofara M Carlès M Raucoules-Aimé M R Sellam J L Horn Effects of intrathecal midazolam on postoperative analgesia when added to a Bupivacaine-Clonidine mixtureReg Anesth Pain Med2006315015

4 

EA Hamber CM Viscomi Intrathecal Lipophilic Opioids as Adjuncts to Surgical Spinal AnesthesiaReg Anesth Pain Med19992432556310.1097/00115550-199924030-00015

5 

R Gertler HC Brown DH Mitchell EN Silvius Dexmedetomidine: A Novel Sedative-Analgesic AgentBaylor Univ Med Center Proc2001141132110.1080/08998280.2001.11927725

6 

TL Yaksh SV Reddy Studies in primate on the analgesic effects associated with intrathecal actions of opiates, alpha-adrenergic agonists, and baclofenAnesthesiology19815445167

7 

H Eid MA Shafie H Youssef Dose related prolongation of hyperbaric bupivacaine spinal anaesthesia by dexmedetomidineAin Shams J Anesthesiol2011428395

8 

SM Al-Ghanem IM Massad MM Al-Mustaf KR Al-Zaben IY Qudaisa AM Qatawn Effect of Adding Dexmedetomidine versus Fentanyl to Intrathecal Bupivacaine on Spinal Block Characteristics in Gynecological Procedures: A Double Blind Controlled StudyAm J Appl Sci200965882710.3844/ajas.2009.882.887

9 

MM Al-Mustafa SA Abu-Halaweh AS Aloweidi MM Aloweidi BA Ammari ZM Awwad Effect of dexmedetomidine added to spinal bupivacaine for urological procedureSaudi Med J20093036570

10 

GE Kanazi MT Aouad SI Jabbour-Khoury MD Al Jazzar MM Alameddine R Al-Yaman Effect of low-dose dexmedetomidine or clonidine on the characteristics of bupivacaine spinal blockActa Anaesthesiol Scand2006502222710.1111/j.1399-6576.2006.00919.x

11 

R Verma M Kohli JK Kushwaha R Gupta J Bogra R Raman A Comparative study of intrathecal dexmedetomidine and fentanyl as adjuvants to BupivacaineJ Anaesthesiol Clin Pharmacol20112733394310.4103/0970-9185.83678

12 

M Elhakim D Abdelhamid H Abdelfattach H Magdy A Elsayed M Elsayed Effect of epidural dexmedetomidine on intraoperative awareness and post-operative pain after one-lung ventilationActa Anaesthesiol Scand2010546703910.1111/j.1399-6576.2009.02199.x

13 

AP Morrison JM Hunter SH Halpern A Banerjee Effect of intrathecal magnesium in the presence or absence of local anaesthetic with and without lipophilic opioids: a systematic review and meta-analysisBr J Anaesth201311057021210.1093/bja/aet064

14 

R Arcioni S Palmisani S Tigano C Santorsola V Sauli S Romanò Combined intrathecal and epidural magnesium sulfate supplementation of spinal anesthesia to reduce post-operative analgesic requirements: a prospective, randomized, double-blind, controlled trial in patients undergoing major orthopedic surgeryActa Anaesthesiol Scand2007514482910.1111/j.1399-6576.2007.01263.x

15 

M Özalevli TO Cetin H Unlugenc T Guler G Isik The effect of adding intrathecal magnesium sulphate to bupivacaine-fentanyl spinal anaesthesiaActa Anaesthesiol Scand200549101514910.1111/j.1399-6576.2005.00793.x

16 

M Özalevli TO Cetin H Unlugenc T Guler G Isik The effect of adding intrathecal magnesium sulphate to bupivacaine-fentanyl spinal anaesthesiaActa Anaesthesiol Scand200549101514910.1111/j.1399-6576.2005.00793.x

17 

MB Khezri S Yaghobi M Hajikhani S Asefzadeh Comparison of postoperative analgesic effect of intrathecal magnesium and fentanyl added to bupivacaine in patients undergoing lower limb orthopedic surgeryActa Anaesthesiol Taiwanica201250192410.1016/j.aat.2012.03.001

18 

PR Bromage A Comparison of the Hydrochloride and Carbon Dioxide Salts of Lidocaine and Prilocaine in Epidural AnalgesiaActa Anaesthesiol Scand19659556910.1111/j.1399-6576.1965.tb00523.x

19 

J Katz R Melzack Measurement of painSurg Clin North Am19997922315210.1016/s0039-6109(05)70381-9

20 

FN Kaya B Yavascaoglu G Turker A Yildirim A Gurbet EB Mogol Intravenous dexmedetomidine, but not midazolam, prolongs bupivacaine spinal anesthesiaCan J Anesth2010571394510.1007/s12630-009-9231-6

21 

MM Al-Mustafa IZ Badran HM Abu-Ali BA Al-Barazangi IM Massad SM Al-Ghanem Intravenous dexmedetomidine prolongs bupivacaine spinal analgesiaMiddle East J Anaesthesiol200920222531

22 

B Erdivanli M Altun OK Sezen SA Colakoğlu Anti-nociceptive, analgesic and pathohistological effects of intrathecaldexmedetomidine and bupivacaine in ratsBraz J Anesthesiol20136321837

23 

MS Smith UB Schumbra KH Wilson SO Page C Hulette AR Light Alpha 2 adrenergic receptor in human spinal cord: Specific localized expression of mRNA encoding alpha-2 adrenergic receptor subtypes at four distinct levelsBrain Res Mol Brain Res19953410917

24 

C Smith G Birnbaum J L Carter J Greenstein FD Lublin Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study GroupNeurology1994443443

25 

P Rahimzadeh SHR Faiz F Imani P Derakhshan S Amniati Comparative addition of dexmedetomidine and fentanyl to intrathecal bupivacaine in orthopedic procedure in lower limbsBMC Anesthesiol20181816210.1186/s12871-018-0531-7

26 

HY Zhong WP Zhang Effect of intravenous magnesium sulfate on bupivacaine spinal anesthesia in preeclamptic patientsBiomed Pharmacother2018108128993

27 

N Banihashem B Hasannasab A Esmaeili B Hasannasab Addition of Intrathecal Magnesium Sulfate to Bupivacaine for Spinal Anesthesia in Cesarean SectionAnesthesiol Pain Med20155310.5812/aapm.5(3)2015.22798

28 

H Omar WA Aboella MM Hassan Comparative study between intrathecaldexmedetomidine and intrathecal magnesiumsulfate for the prevention of post-spinal anaesthesia shivering in uroscopic surgery; (RCT)BMC Anesthesiol2019191190

29 

L He JM Xu SM Liu ZJ Chen X Li R Zhu IntrathecalDexmedetomidine Alleviates Shivering during Cesarean Delivery under Spinal AnesthesiaBiol Pharm Bull201740216973

30 

M Bouchnak N Belhadj T Chaaoua W Azaiez M Hamdi H Maghrebi Rachianesthésie pour césarienne: la vitessed'injection a-t-elleune influence surl'incidence de l'hypotension? [Spinal anaesthesia for Caesarean section: dose injection speed have an effect on the incidence of hypotension?Ann Fr Anesth Reanim2006251179

31 

G Shoeibi M Sadegi A Firozian F Tabassomi The Additional Effect of Magnesium Sulfate to Lidocaine in Spinal Anesthesia for Cesarean SectionInt J Pharmacol200735425710.3923/ijp.2007.425.427



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.